(Q39373494)

11 September 2017

title

Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro (English)

1 reference

11 September 2017

1 reference

J Mani

1

1 reference

11 September 2017

S Vallo

2

1 reference

11 September 2017

K Barth

3

1 reference

11 September 2017

J Makarević

4

1 reference

11 September 2017

E Juengel

5

1 reference

11 September 2017

G Bartsch

6

1 reference

11 September 2017

C Wiesner

7

1 reference

11 September 2017

A Haferkamp

8

1 reference

11 September 2017

R A Blaheta

9

1 reference

11 September 2017

language of work or name

1 reference

27 March 2012

1 reference

Prostate Cancer and Prostatic Diseases

11 September 2017

published in

1 reference

11 September 2017

volume

15

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

250-255

1 reference

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Bisphosphonate stimulation of osteoblasts and osteoblastic metastasis as a mechanism of hypocalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Beta1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

31 March 2020

Identifiers

DOI

10.1038/PCAN.2012.9

1 reference

11 September 2017

1 reference